FDA Warning Letter to Aversa's Italian Bakery (2026-05-20) — CGMP/Hazard Analysis/Risk-Based Preventive Controls for Food/Adulterated
Letter issued · posted to fda.gov .
Subject as published: CGMP/Hazard Analysis/Risk-Based Preventive Controls for Food/Adulterated
TL;DR
In short: FDA issued a Warning Letter to Aversa's Italian Bakery on 2026-05-20 citing: CGMP/Hazard Analysis/Risk-Based Preventive Controls for Food/Adulterated. Full letter: https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/aversas-italian-bakery-722904-05202026
Argus analysis
Aversa's Italian Bakery (MARCS-CMS 722904) received an FDA Warning Letter dated May 20, 2026 from the Human Foods Program. The letter cites: CGMP/Hazard Analysis/Risk-Based Preventive Controls for Food/Adulterated. FDA posts Warning Letters to fda.gov after an internal review period; this one was made public on June 2, 2026.
CGMP citations typically reference 21 CFR Part 211 (finished pharmaceuticals) or Part 111 (dietary supplements), covering subjects such as identity testing of incoming components, validated cleaning procedures, batch-failure investigations, and stability program design. Repeat or systemic findings are what typically drive FDA toward import alert or consent decree escalation.
FDA Warning Letters typically specify a 15-working-day response window for the recipient to detail corrective actions. Compliance teams at peer companies in the same CGMP (Current Good Manufacturing Practice) category commonly use a newly published letter as a prompt to re-check their own procedures against the same citation, and to watch fda.gov for a close-out letter confirming the cited firm's corrective action was accepted — or, absent one, for escalation to import alert, injunction, or product seizure.
Severity context
Critical severity. Typically reserved for data integrity, sterile-product CGMP, or repeat violations — matters that historically precede injunctions, consent decrees, or import alerts.
Regulatory background
CGMP citations typically reference 21 CFR Part 211 (drugs) or 21 CFR Part 600 (biologics). Common subjects include identity testing of incoming components (211.84), validated cleaning procedures (211.67), and stability program design (211.166).
What peer compliance teams typically do next
Most compliance officers at peer companies use a Warning Letter against a named entity as a checklist for their own CAPA program. Common steps: pull the verbatim FDA letter; map each cited 21 CFR section against the team’s SOP library; confirm CAPA coverage; brief the QMR (Quality Management Review) on whether the cited subject matter is in scope for the next internal audit. The 15-business-day response window applies to the cited entity, not to peers — but a documented internal review against the cited subjects is what regulators expect to see if a peer is later inspected on the same topic.
Excerpt from the FDA Warning Letter (public domain, 17 USC §105)
WARNING LETTER Aversa's Italian Bakery MARCS-CMS 722904 — May 20, 2026 More Warning Letters Warning Letters About Warning and Close-Out Letters Delivery Method: VIA Electronic Mail Product: Food & Beverages Recipient: Recipient Name Rafael Aversa, Sr. Recipient Title Owner Aversa's Italian Bakery 801 Route 168 Turnersville , NJ 08012-1472 United States doughboyra@yahoo.com Issuing Office: Human Foods Program United States May 20, 2026 WARNING LETTER Re: CMS # 722904 Dear Mr. Rafael Aversa, Sr.: The United States Food and Drug Administration (FDA) conducted an inspection at your food manufacturing facility, Aversa's Italian Bakery, located at 801 Route 168, Turnersville, NJ 08012-1472, between August 11, 2025, and August 19, 2025. During our inspection, the investigator found significant violations of the Current Good Manufacturing Practice, Hazard Analysis, and Risk-Based Preventive Controls for Human Food regulation, Title 21, Code of Federal Regulations, Part 117 (21 CFR Part 117). In addition, during the inspection, FDA collected finished product samples of steak rolls from your production facility, and the analytical results confirmed the presence of unintended sesame in this product. Based on FDA’s inspectional findings and analytical results for samples collected from your facility, we determined that your ready-to-eat (RTE) bakery products are adulterated within the meaning of section 402(a)(4) of the Federal Food, Drug, and Cosmetic Act (the Act) [21 U.S.C. § 342(a)(4)] in that they were prepared, packed, or held under insanitary conditions whereby they may have become contaminated with filth or whereby they may have been rendered injurious to health. In addition, failure of the owner, operator, or agent in charge of a covered facility to comply with the preventive controls provisions of the CGMP & PC rule (located in subparts A, B, C, D, E, F, and G of Part 117) is prohibited by section 301(uu) of the Act [21 USC § 331(uu)]. A label review was also conducted on your Catering Kaiser, Catering Torpedo, Kaiser Roll, and Steak Roll products which found violations of Food Labeling regulation, Title 21, Code of Federal Regulations, Part 101 (21 CFR Part 101) rendering them to be misbranded within the meaning of section 403 of the Act [21 U.S.C. § 343]. You may find the Act and further information about FDA’s regulations through links in FDA’s home page at http://www.fda.gov. At the conclusion of the inspection, FDA issued an FDA Form 483 (FDA-483), Inspectional Observations, listing the violations found at your facility. FDA received your firm’s emailed responses to the FDA-483 on August 27, 2025, and October 24, 2025, describing corrective actions taken by your firm. After reviewing the inspectional findings and your firm’s responses, we are issuing this letter to advise you of FDA’s continuing concerns and to provide detailed information describing the findings at your facility. We also address your responses below. Hazard Analysis and Risk-…
Excerpt only. The full verbatim Warning Letter is the source of truth — always read the original before regulatory decisions.
The verbatim FDA Warning Letter is the source of truth. Always read the original before acting on any analysis or summary on this page.
Read the full letter on fda.gov ↗Frequently asked questions
- When did FDA issue the warning letter to Aversa's Italian Bakery?
- FDA issued the letter (MARCS-CMS 722904) on 2026-05-20 and posted it publicly on fda.gov on 2026-06-02.
- Is the FDA warning letter to Aversa's Italian Bakery publicly available?
- Yes. The full verbatim letter is published at fda.gov. Argus HQ links directly to the source: https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/aversas-italian-bakery-722904-05202026.
- What does a "critical" severity rating mean for this letter?
- Critical severity. Typically reserved for data integrity, sterile-product CGMP, or repeat violations — matters that historically precede injunctions, consent decrees, or import alerts.
- What is the regulatory background for a CGMP — Current Good Manufacturing Practice warning letter?
- CGMP citations typically reference 21 CFR Part 211 (drugs) or 21 CFR Part 600 (biologics). Common subjects include identity testing of incoming components (211.84), validated cleaning procedures (211.67), and stability program design (211.166).
argus.hq
Don’t find out about the next one six weeks late.
Argus reads every FDA Warning Letter the day it publishes, summarizes it against your watchlist, and lands the ones touching your business in your inbox at 6am ET. $199/month. Cancel any time.
methodology
The analysis above is produced by Anthropic Claude Haiku 4.5 against the verbatim FDA Warning Letter excerpt and is brand-voice lint-checked before publish. The TL;DR is the same summary that ships in the customer email digest. Severity is auto-classified by Argus from the subject string and letter body using rules documented in lib/ingestion/fda-warning-letters.ts.
Argus HQ is informational only. Summaries and analyses are AI-generated and may contain errors, misclassifications, or omissions. Verify against the FDA source URL above. Argus HQ is not a law firm, accounting firm, or regulatory agency, and provides no legal, accounting, financial, medical, or regulatory advice.
Compiled by Argus HQ Research from FDA primary sources · Reviewed by Andy Gaber, Founder
Cite this record
Reusing this data in reporting or research? Here’s a ready-made citation.
Argus HQ Research (2026). FDA Warning Letter to Aversa's Italian Bakery (2026-05-20) — CGMP/Hazard Analysis/Risk-Based Preventive Controls for Food/Adulterated. Digital Empire LLC. Retrieved from https://argushq.ai/fda/warning-letter/fda-wl-aversa-s-italian-bakery-2026-05-20-cgmp
"FDA Warning Letter to Aversa's Italian Bakery (2026-05-20) — CGMP/Hazard Analysis/Risk-Based Preventive Controls for Food/Adulterated." Argus HQ Research, Digital Empire LLC, 2026, argushq.ai/fda/warning-letter/fda-wl-aversa-s-italian-bakery-2026-05-20-cgmp.
Argus HQ Research. "FDA Warning Letter to Aversa's Italian Bakery (2026-05-20) — CGMP/Hazard Analysis/Risk-Based Preventive Controls for Food/Adulterated." Digital Empire LLC. Accessed July 13, 2026. https://argushq.ai/fda/warning-letter/fda-wl-aversa-s-italian-bakery-2026-05-20-cgmp.
@misc{argushq_argushq_ai_fda_warning_letter_fda_wl_aversa_s_italian_bakery_2026_05_20_cgmp_2026,
title = {FDA Warning Letter to Aversa's Italian Bakery (2026-05-20) — CGMP/Hazard Analysis/Risk-Based Preventive Controls for Food/Adulterated},
author = {{Argus HQ Research}},
year = {2026},
publisher = {Digital Empire LLC},
url = {https://argushq.ai/fda/warning-letter/fda-wl-aversa-s-italian-bakery-2026-05-20-cgmp},
note = {Accessed: July 13, 2026}
}